spective studies with BEV-free control groups are required to better define the role of BEV among the limited options in patients with recurrent grade II/III gliomas.
glioblastoma in uncontrolled phase II trials, leading to its registration in the USA and other countries [4, 5] . Despite concerns regarding the lack of durable responses and the failure to demonstrate of an overall survival (OS) benefit, the use of BEV in recurrent glioma has widely spread to other glioma entities. This may be due to beneficial effects of BEV on performance status and steroid use [6] and the apparent lack of alternative options after the failure of alkylating agent therapy.
The role of BEV alone or in combination with irinotecan in recurrent grade II and III gliomas has been less well studied than in glioblastoma, particular in Europe. We here report a retrospective analysis on the safety and efficacy of BEV alone or in combination with irinotecan in patients with recurrent grade II and III gliomas.
Patients and Methods
We reviewed the reports of 39 unselected patients with grade II and grade III gliomas from three institutions (Heidelberg, Zurich, St. Gallen) who received BEV for progressive or recurrent disease either as a single agent or in combination with irinotecan between 2007 and 2011. BEV was commonly administered at 10 mg/kg, and irinotecan at 125 mg/m 2 without use of enzyme-inducing antiepileptic drugs and at 340 mg/m 2 with use of enzymeinducing antiepileptic drugs, both at 2-weekly intervals. Radiological response to BEV-based therapy was formally re-evaluated using both Macdonald and RANO criteria [7, 8] for this analysis at the sites without a post hoc central review. Clinical benefit was defined by an improvement or stabilization of clinical symptoms, improvement of Karnofsky performance score (KPS) of 6 10, or reduction of steroid use. The assessment of adverse events was restricted to the period of BEV therapy. Toxicity data were collected retrospectively using NCI common toxicity criteria (version 4.0). PFS and OS rates were calculated from the first dose of BEV until progression and death. Survival after progression under BEV was assessed from the date of progression until death. Progression and death did not occur before the arbitrarily chosen cut-off date of October 1, 2011 in 5 and 14 patients, respectively. These patients were censored at this cut-off date. One patient was lost to follow-up before the cut-off date and was censored at the last date of MRI assessment. Data were analyzed by the KaplanMeier estimation method and statistical significance was determined by log-rank test (Mantel-Cox) using the software of GraphPad Prism software version 5.0 (San Diego, Calif., USA).
Results

Study Population and Pretreatment Characteristics
Detailed patient characteristics are summarized in table 1 . 39 patients were identified: all patients had been pretreated with temozolomide and some patients also with nitrosourea-based chemotherapy. All but 1 patient had received radiotherapy. Another patient with an extensive grade II glioma, previously treated with temozolomide, opted against radiotherapy. The median number of relapses before the administration of BEV-based regimens was 3 in the monotherapy group and 4.5 in the combination group. It was 4 for grade II tumors and 3 for grade III tumors.
Treatment 27 patients, 14 with grade II and 13 with grade III glioma and a median KPS of 80 were treated with BEV alone, and 12 patients, 7 with grade II and 5 with grade III glioma and a median KPS of 90 received BEV in combination with irinotecan. The duration of BEV treatment was 3.6 months for monotherapy and 4.5 months with the combination ( table 2 ). Interruption of therapy for more than 4 weeks occurred in 6 of 39 patients because of patients' or physicians' decisions.
Toxicity
Both BEV monotherapy and BEV in combination with irinotecan were generally well tolerated ( table 3 ) . Arterial hypertension was a common adverse event with an overall incidence of 26% in the monotherapy and 33% in the combination group. Grade 4 leukopenia was observed in 1 patient only. No thromboembolic events or hemorrhages were reported.
Outcome
Some clinical benefit was noted in more than half of the patients ( table 2 ) . A KPS increase of 10% was seen in 14.8% of patients with BEV alone and 8.3% of patients with BEV in combination. No patient had an increase in KPS of 20% or more. 26% of the patients in the BEV monotherapy and 33% in the combination group achieved a partial response (PR) as assessed by Macdonald and by RANO criteria ( table 2 ). The median duration of the best response was 3.9 months in the monotherapy group and 3.5 months in the combination group.
The PFS was different in 1 patient when using RANO criteria instead of Macdonald criteria. It was progressive disease instead of stable disease because of a progressive FLAIR lesion. In this patient, PFS by RANO was considered to be valid by the site and entered into our database. The comparison of PFS and OS between BEV monotherapy and combination with irinotecan did not indicate major differences either for all patients pooled or separated by grade or histology ( fig. 1 ; table 2 ). For the grade II and III tumors pooled, the median PFS was 4.2 months disease under BEV until the indicated cut-off date. BEV was continued as a monotherapy or in any combination therapy in 15 patients while BEV was stopped in 16 patients. Up to failure, treatment duration with BEV was 16 weeks in those who continued as opposed to 15 weeks in those who did not. Median OS from progressive disease under BEV was 55 weeks with BEV versus 8.5 weeks without BEV (p = 0.0022) ( fig. 2 ) . Interestingly, only 1 patient out of 12 (8%) of the combination group continued a BEVcontaining regimen in contrast to 14 out of 27 (52%) patients in the monotherapy group. This may indicate a less favorable toxicity profile in the combination group. The observation that BEV was more likely to be continued when administered as a single agent may be one explanation on the observed benefit on OS in the BEV monotherapy group.
Discussion
This retrospective study confirms and extends the current knowledge on the safety and efficacy of BEVbased therapy for progressive or recurrent gliomas of WHO grades II and III. Table 4 provides an overview about the current literature available on this topic. In line with previous data, BEV was well tolerated with hypertension as a known risk to take care of [9] . An increased toxicity with the addition of irinotecan did not become apparent in this small patient population. However, the toxicity data have to be interpreted with caution since retrospective studies tend to underestimate toxicity.
Based on the perception that BEV has mainly an effect on contrast-enhancing tumor, the activity of BEV in lowgrade tumors may be limited. However, previous reports as well as our current study suggest at least moderate activity for BEV in recurrent grade II and grade III gliomas. This may be due to a high proportion of secondary malignant progression of the tumor. In our series, all but 1 patient had contrast-enhancing tumor prior to institution of BEV, and progression to a higher histological grading was common in patients undergoing second surgery. Patients with grade II tumors had a higher median number of treatments for relapse or progression than patients with grade III tumors prior to BEV (4 vs. 3) . This may explain the apparent lack of a difference in outcome from BEV by tumor grade in this series.
Response rates and data for PFS and OS ( table 2 ) are  comparable with previously published results ( table 4 ) . The retrospective nature of this study limits the reliability of our data on clinical benefit, but at least half of the patients appeared to have improved with BEV, albeit transiently. Chamberlain and Johnston [10, 11] reported retrospective data of patients with recurrent anaplastic astrocytoma (n = 25) and anaplastic oligodendroglioma (n = 22) treated with BEV as a single agent with a PFS-6 of 60 and 68% and a median OS of 9 and 8 months. However, a prospective study evaluating BEV as a single agent in 31 patients with recurrent anaplastic glioma did not meet the primary endpoint of a PFS-6 of 50% [12] . Desjardins et al. [13] reported modest activity for the combination of BEV with irinotecan (n = 33) with a PFS-6 of 55% and median OS of 15 months in a prospective phase II trial of recurrent anaplastic gliomas. This compares favorably with data from two similar but retrospective studies indicating PFS-6 rates of 39% for a mixed population of anaplastic glioma and glioblastoma [14] and 42% for grade II and grade III oligodendroglioma [15] . Similarly, our retrospective data do not indicate an additional value of the combination therapy compared with BEV alone. Response assessments in the discussed studies were based on Macdonald criteria [7] . Aware of possibly alternative patterns of progression during anti-angiogenic therapy especially regarding non-enhancing T2 and FLAIR tumor volume, we additionally determined response rates using the new RANO criteria [8, 14] . In 1 of 39 patients, the use of the RANO criteria showed a different result. Thus, the introduction of these novel criteria may alter response assessment and result in a change in treatment only in a minority of patients. The use of BEV in malignant glioma is often continued beyond progression because ill-defined rebound phenomena are feared. However, there is little evidence supporting the perception that withdrawing BEV is worse than continuing the drug after it has failed. In a small retrospective study, there was no significant difference in survival of highgrade glioma patients after a BEV-free regimen compared to the continued use BEV (91 vs. 116 days) [16] . Similarly, a recent meta-analysis of four phase II studies conducted in patients with recurrent grade III gliomas did not show a significant difference between BEV-containing or noncontaining salvage therapies after BEV failure for OS [17] . Our retrospective analysis suggests a prolonged OS if BEV is continued beyond progression. However, the interpretation of these data is difficult because the probability of a preselection of this patient population is high. The decision of continuing or withdrawing BEV is likely to have been influenced by clinical performance status, age, patients' and physicians' preferences. To address this question, a prospective trial design including randomization of patients will be necessary.
In conclusion, there is evidence that BEV has activity not only in recurrent glioblastoma but also in grade II and grade III glioma. The effect on OS remains uncertain. In recurrent grade II and grade III glioma, a prospective phase II randomized study evaluating the efficacy of BEV with or without temozolomide (TAVAREC, EORTC 26091, NCT01164189) has started accrual. This trial and further prospective and randomized trial data will be needed for a better evaluation of the role of BEV as a single agent and in combination with other agents in order to improve the limited therapeutic options for patients with recurrent gliomas failing radiotherapy and alkylating agent chemotherapy. 
